Following U.S. Stocks are among the “Top Gainers” Stocks in the course of recent trading session, Monday: Capnia Inc (NASDAQ:CAPN), Origin Agritech Ltd (NASDAQ:SEED), ImmunoGen, Inc (NASDAQ:IMGN), Paragon Offshore PLC (NYSE:PGN), VolitionRX Ltd (NYSEMKT:VNRX)
On March 10, 2015, (Capnia Inc (NASDAQ:CAPN), stated financial results for the fourth quarter and twelve months ended December 31, 2014.
Fourth Quarter 2014 Financial Results:
No income was recognized in the three months ended December 31, 2014 or December 31, 2013.
Research and development expenses in the fourth quarter of 2014 were $0.6 million, contrast to $0.4 million in the fourth quarter of 2013. The raise was primarily due to reimbursement of R&D expense of $0.3 million under the GSK license contract in the fourth quarter of 2013. The GSK license contract was terminated in the second quarter of 2014. Exclusive of this reimbursement R&D expenses were largely constant in both quarters.
Sales and marketing expenses in the fourth quarter of 2014 were $0.2 million. There were no sales and marketing expenses for the year ended December 31, 2013. The raise was primarily due to the addition of the Vice President of Sales in June 2014 and the commercial launch activities for CoSense initiated in October 2014.
General and administrative expenses in the fourth quarter of 2014 rose to $1.1 million, contrast to $0.2 million in the fourth quarter of 2013. The raise was primarily due to a raise in consulting costs, employee related costs due to raised headcount and a raise in stock based compensation expense of $0.3 million in 2014 as compared to 2013.
Capnia Inc (NASDAQ:CAPN), skyrocketed 28.86%, and is now trading at $6.96. The Stock is active as 1.23M shares changed hands versus its average volume of 1.15M shares. The stock has price to cash ratio of 4.55. With recent incline, the year-to-date (YTD) performance reflected a 353.33% gain above last year. During the past month the stocks gain 24.77%, bringing three-month performance to 312.12% and six-month performance to 75.26%.
Capnia, Inc. develops and commercializes therapeutics and diagnostics products. The company offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition that causes long-term developmental disability due to degradation of red blood cells. It also develops Serenz, a therapeutic product candidate that has accomplished Phase II clinical trials for the treatment of symptoms related to allergic rhinitis. The company was founded in 1999 and is based in Redwood City, California.
Origin Agritech Ltd (NASDAQ:SEED)’s shares picked up 29.81%, and is now trading at $1.35. The Stock is active as 384,469.00 shares changed hands versus its average volume of 82,940.00 shares. The stock volatility for the week is 4.82%, while for the month remained 4.65%. The company holds consensus target price of $5.00.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.06 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -240.00% and Annual EPS growth for the past 5 years is considered as 24.20%.
Origin Agritech Limited, an agricultural biotechnology company, engages in crop seed breeding and genetic improvement activities in the People’s Republic of China. The company is involved in the research and development, production, sale, and marketing of crop seeds; and provision of related technical services. It primarily offers hybrid varieties of corn, rice, and canola seeds. The company distributes its products to farmers through distributors and retailers. Origin Agritech Limited was founded in 1997 and is based in Beijing, the People’s Republic of China.
ImmunoGen, Inc (NASDAQ:IMGN), recently declared that Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology – counting ImmunoGen’s new DNA-acting IGN payload agents – to develop and commercialize targeted anticancer therapeutics to up to two unrevealed targets. The agreement also provides Takeda with the option to take a license for a third target for an additional upfront fee. ImmunoGen will receive $20 million upfront and – for each target – is eligible to receive milestone payments potentially totaling up to $210 million plus royalties on the commercial net sales of any resulting ADC products. Takeda is responsible for the development, manufacturing and marketing of any ADC products resulting from this contract.
ImmunoGen, Inc (NASDAQ:IMGN), enhanced 18.01%, and is now trading at $8.77. The Stock is active as 3.59M shares changed hands versus its average volume of 970,419.00 shares. The company holds the market capitalization of $747.42M. For the last twelve months, the stock was able to keep return on equity at -93.80%, while return on assets at -46.60%, in response to its return on investment at -94.50%. Its 20-day moving average gained 8.38%, above 50-day moving average of 16.66%, below 200-day moving average of -13.18% from the latest market price of $8.33. The mean recommendation of analysts for this stock is 2.70.(where 1=Buy, 5=Sale).
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates comprise IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia.
Paragon Offshore PLC (NYSE:PGN), rose 11.19%, and is now trading at $1.49. The Stock is active as 514,246.00 shares changed hands versus its average volume of 2.71M shares. The stock has volatility for the week is 17.39%, while for the month it is 14.13%. The company has the market capitalization of $114.60M. The company holds the book value per share of 5.26, whereas cash per share is 0.81. Price to book ratio remained 0.25, while price to sale ratio is 0.06. Analysts mean recommendation for the stock is said to be 2.80 (where 1=Buy, 5=sale).
Paragon Offshore plc, together with its subsidiaries, provides offshore drilling rigs. The company is involved in contracting its rigs, related equipment, and work crews to conduct oil and gas drilling and workover operations for its exploration and production customers on a day rate basis. Its drilling fleet comprises of 34 jackups and 6 floaters, counting 4 drillships and 2 semisubmersibles. The company has operations in Mexico, Brazil, the North Sea, West Africa, the Middle East, India, and Southeast Asia. Paragon Offshore plc was incorporated in 2014 and is headquartered in Houston, Texas.
VolitionRX Ltd (NYSEMKT:VNRX), raised 10.00%, and is now trading at $4.40. The Stock is active as 15,435.00 shares changed hands versus its average volume of 47,874.00 shares. The stock has price to sale ratio of 4852.50. With recent incline, the year-to-date (YTD) performance reflected a 15.53% gain below last year. During the past month the stocks gain 8.66%, bringing three-month performance to 14.03% and six-month performance to -12.2%. The mean recommendation of analysts for this stock is 2.00.(where 1=Buy, 5=Sale).
VolitionRX Limited, a development stage life sciences company, focuses on developing cancer detection blood tests for detecting and diagnosing cancer and other diseases. It develops two blood tests in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer and nucleosomes containing specific histone variants. The company also develops nine blood tests in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones, the proteins that package, and order DNA into nucleosomes; and five blood tests in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts, in addition to offers research kits.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
